Emcure

Pharmaceuticals

Emcure Pharmaceuticals is an Indian multinational pharmaceutical company headquartered in

Pune, Maharashtra. Emcure's product portfolio includes tablets, capsules (both Softgel capsules
and hard-gel capsules) and injectables.[1][2]
 Emcure Pharmaceuticals Limited

Type MNC (JVs and subsidiaries)

Industry Pharmaceutical

Founded 1983

Founder Satish Mehta (CEO)

Headquarters Hinjwadi, Pune, India

Area served Worldwide

Key people Namita Thapar

(Executive Director)
Vik Thapar
(President - Corporate Dev & Strategy)
Samit Mehta
(President - R&D)

Products Tablets
capsules
softgels
injectables
Lyophilized sterile parenterals
Onco products

Revenue ₹ 6091.80 Crore

(US$ 870.25 million) (FY2021)

Net income ₹ 418.59 Crore

(US$ 59.78 million) (FY2021)

Number of employees 11000+ (2021)

Website www.emcure.com (https://emcure.com/)

Indian plants

This is the list of Manufacturing facilities based in India[3] -

 Solid Dosage facility at Hinjawadi - In 2006, Emcure received US FDA approval for its solid
dosages facility at Hinjwadi, Pune. The plant manufactures solid oral formulations for the
international regulated markets.

Small volume parenteral facility at Hinjawadi - US FDA, UK MHRA approved. Has lyophilization
and pfs capability

Oncology injectable facility at Hinjawadi

Solid Orals facilities at Jammu and Bhosari

API facility at Kurkumbh- US FDA approved

Biotech facility at Hinjawadi

R&D center at Gandhinagar and plant at Sanand, Ahmedabad.- Sanand facility is US FDA
approved

US plant

USA - The company has a manufacturing facility and R&D center in East Brunswick, New Jersey,
USA.[3]

Capital markets

Emcure is planning to raise money through an initial public offering for some time now[4] In 2014,
Blackstone sold its stake in Emcure to Bain Capital[5]

Recalls

In 2010, Pfizer had to recall three batches of an anti-bacterial product from the US market due to
presence of Bacillus anthracis, Penicillium chrysogenum & E. coli in some samples.[6] Teva
recalled several batches of two products due to white tablets showing presence of Yersinia
pestis in 2011.[7]

AIDS Initiative

Emcure voices its concerns on HIV/AIDS through its "Let's fight AIDS together" initiative and
supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social
responsibility it supports 'Taal', a pharmacy for HIV/AIDS patients run by HIV/AIDS patients.

Emcure has license agreements with Bristol-Myers Squibb for Atazanavir[8] and Gilead Sciences
for Tenofovir as part of their Global Access Programs.

Anticancer portfolio

Roche has signed a deal with Emcure for manufacturing its blockbuster anticancer drugs
Herceptin and Mabthera in India.[6] Under this programme the cancer drugs shall be made
available to the developing world at an affordable 'cut-price' version.[9]

Price fixing

Heritage Pharmaceuticals, a division of Emcure has entered into a deferred prosecution

agreement[10] with the United States Department of Justice, Antitrust Division ("DOJ") relating to
a one-count Information for a conspiracy involving glyburide. In conjunction with the DPA,
Heritage will pay a $225,000 fine.

In addition, the Company separately agreed to a settlement with the United States Department of
Justice, Civil Division to resolve potential civil liability under the False Claims Act in connection
with the antitrust conduct. Under the terms of the settlement, the Company has agreed to pay
$7.1 million. Heritage has agreed to pay $7.1 million as part of a settlement with DOJ's Civil
Division to resolve allegations of selling drugs at the artificially inflated prices, which resulted in
claims submitted to or purchases by federal healthcare programs

References

1. "Emcure Pharmaceuticals | Leading Global Pharmaceutical Company" (https://www.emcure.com/) .

Emcure. Retrieved 2021-08-23.

2. "Emcure Pharmaceuticals: Latest News & Videos, Photos about Emcure Pharmaceuticals | The Economic
Times - Page 1" (https://economictimes.indiatimes.com/topic/Emcure-Pharmaceuticals) . The
Economic Times. Retrieved 2021-08-23.

3. "Manufacturing | Emcure Pharmaceuticals" (https://www.emcure.com/manufacturing-overview/) .

Emcure. Retrieved 2021-08-23.

4. "Latest News: India News | Latest Business News | BSE | IPO News" (https://www.moneycontrol.com/n
ews/) . Moneycontrol.
 5. "Blackstone to sell Emcure Pharmaceuticals stake to Bain Capital - Indian Express" (http://archive.indiane
xpress.com/news/blackstone-to-sell-emcure-pharmaceuticals-stake-to-bain-capital/1209682/) .
archive.indianexpress.com.

6. "Business News Today: Read Latest Business news, India Business News Live, Share Market & Economy
News" (https://economictimes.indiatimes.com/) . The Economic Times.

7. "Archived copy" (https://web.archive.org/web/20110520185024/http://recalls.org/d2011-03.htm) .

Archived from the original (http://www.recalls.org/d2011-03.htm) on 2011-05-20. Retrieved
2012-04-25.

8. Bureau, Our Corporate (February 17, 2006). "Bristol-Myers outsources AIDS drug to Emcure" (https://ww
w.business-standard.com/article/Companies/Bristol-Myers-outsources-AIDS-drug-to-Emcure-106021701
143_1.html) – via Business Standard.

9. "Archived copy" (https://archive.today/20120801012234/http://www.businessworld.in/businessworld/bu

sinessworld/content/Roche-Sell-Cheaper-Cancer-Drugs-India.html?print=yes) . Archived from the
original (http://www.businessworld.in/businessworld/businessworld/content/Roche-Sell-Cheaper-Cancer
-Drugs-India.html?print=yes) on 2012-08-01. Retrieved 2012-04-12.

10. "Pharmaceutical Company Admits to Price Fixing in Violation of Antitrust Law, Resolves Related False
Claims Act Violations" (https://www.justice.gov/opa/pr/pharmaceutical-company-admits-price-fixing-viol
ation-antitrust-law-resolves-related-false) . www.justice.gov. May 31, 2019.

External links

Emcure website (https://emcure.com/)

Retrieved from
"https://en.wikipedia.org/w/index.php?
title=Emcure_Pharmaceuticals&oldid=1058045395
"
Last edited 21 days ago by Rlink2